HAL (France)
open access
What can artificial intelligence bring to Alzheimer’s disease clinical trials? A first perspective
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ethical considerations of artificial intelligence in dementia research: a review of reviews.#1054232
- Health-related factors and their impact on blood-based biomarkers of Alzheimer's disease / Carolin Kurz, Marleen Taute, Paulina Tegethoff, Anna Hufnagel, Sophia Leonhardt, Selim Üstün Gürsel, Carolin Koriath, Alexander Jethwa, Gwendlyn Kollmorgen, Tobias Bittner, Daniel Keeser, Matthias Brendel, Jan Haeckert, Julia Utecht, Boris Papazov, Johannes Levin, Günter Höglinger, Boris-Stephan Rauchmann, Robert Perneczky#783922
- Treatments for Alzheimer’s and the declaration of Helsinki#291783
- Artificial Intelligence Applied to clinical trials: opportunities and challenges#964418
- Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics#161197
Record · ID 161340
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive